hexamethylene bisacetamide has been researched along with 1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basile, A; Brando, B; Cecchinato, V; Chiaramonte, R; Comi, P; Erba, E; Fazi, C; Scarpati, B | 1 |
1 other study(ies) available for hexamethylene bisacetamide and 1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol
| Article | Year |
|---|---|
Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines.
Topics: Acetamides; Antineoplastic Agents; Cell Line, Tumor; Cyclin-Dependent Kinase 4; gamma-Aminobutyric Acid; Humans; Leukemia-Lymphoma, Adult T-Cell; Proto-Oncogene Proteins c-bcl-2; Receptor, Notch1; Signal Transduction; Triglycerides; Tumor Suppressor Protein p53 | 2008 |